Business
AI summaryCaptor Therapeutics Spolka Akcyjna is a biopharmaceutical company developing therapeutic molecules to treat oncological and autoimmune diseases in Poland. Its targeted protein degradation technology, built on the Optigrade drug discovery platform, aims to destroy disease-causing proteins that resist inhibitors and antibody drugs. The pipeline includes viadrudomide in a Phase 1 trial for liver and lung cancers and rare cancers, the MCL-1 degrader vratitoclax, NEK7 degraders (CT-02B and CT-02S) in preclinical work for neuroinflammation and autoimmune indications, and the PKCtheta degrader CT-05, alongside earlier discovery-stage projects and novel E3 ligases. The company was incorporated in 2015 and is headquartered in Wroclaw, Poland.
